These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 22724029

  • 1. Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.
    Musa A, Khalil E, Hailu A, Olobo J, Balasegaram M, Omollo R, Edwards T, Rashid J, Mbui J, Musa B, Abuzaid AA, Ahmed O, Fadlalla A, El-Hassan A, Mueller M, Mucee G, Njoroge S, Manduku V, Mutuma G, Apadet L, Lodenyo H, Mutea D, Kirigi G, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tafes H, Mekonnen Y, Makonnen E, Ndegwa S, Sagaki P, Kimutai R, Kesusu J, Owiti R, Ellis S, Wasunna M.
    PLoS Negl Trop Dis; 2012; 6(6):e1674. PubMed ID: 22724029
    [Abstract] [Full Text] [Related]

  • 2. Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme.
    Kimutai R, Musa AM, Njoroge S, Omollo R, Alves F, Hailu A, Khalil EA, Diro E, Soipei P, Musa B, Salman K, Ritmeijer K, Chappuis F, Rashid J, Mohammed R, Jameneh A, Makonnen E, Olobo J, Okello L, Sagaki P, Strub N, Ellis S, Alvar J, Balasegaram M, Alirol E, Wasunna M.
    Clin Drug Investig; 2017 Mar; 37(3):259-272. PubMed ID: 28066878
    [Abstract] [Full Text] [Related]

  • 3. Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial.
    Hailu A, Musa A, Wasunna M, Balasegaram M, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tesfaye S, Makonnen E, Khalil E, Ahmed O, Fadlalla A, El-Hassan A, Raheem M, Mueller M, Koummuki Y, Rashid J, Mbui J, Mucee G, Njoroge S, Manduku V, Musibi A, Mutuma G, Kirui F, Lodenyo H, Mutea D, Kirigi G, Edwards T, Smith P, Muthami L, Royce C, Ellis S, Alobo M, Omollo R, Kesusu J, Owiti R, Kinuthia J, Leishmaniasis East Africa Platform (LEAP) group.
    PLoS Negl Trop Dis; 2010 Oct 26; 4(10):e709. PubMed ID: 21049059
    [Abstract] [Full Text] [Related]

  • 4. Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial.
    Musa AM, Mbui J, Mohammed R, Olobo J, Ritmeijer K, Alcoba G, Muthoni Ouattara G, Egondi T, Nakanwagi P, Omollo T, Wasunna M, Verrest L, Dorlo TPC, Musa Younis B, Nour A, Taha Ahmed Elmukashfi E, Ismail Omer Haroun A, Khalil EAG, Njenga S, Fikre H, Mekonnen T, Mersha D, Sisay K, Sagaki P, Alvar J, Solomos A, Alves F.
    Clin Infect Dis; 2023 Feb 08; 76(3):e1177-e1185. PubMed ID: 36164254
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia.
    Tamiru A, Mohammed R, Atnafu S, Medhin G, Hailu A.
    PLoS Negl Trop Dis; 2021 Aug 08; 15(8):e0009713. PubMed ID: 34464401
    [Abstract] [Full Text] [Related]

  • 6. Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan.
    Atia AM, Mumina A, Tayler-Smith K, Boulle P, Alcoba G, Elhag MS, Alnour M, Shah S, Chappuis F, van Griensven J, Zachariah R.
    Trop Med Int Health; 2015 Dec 08; 20(12):1674-84. PubMed ID: 26427033
    [Abstract] [Full Text] [Related]

  • 7. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy.
    Melaku Y, Collin SM, Keus K, Gatluak F, Ritmeijer K, Davidson RN.
    Am J Trop Med Hyg; 2007 Jul 08; 77(1):89-94. PubMed ID: 17620635
    [Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
    Rahman R, Goyal V, Haque R, Jamil K, Faiz A, Samad R, Ellis S, Balasegaram M, Boer MD, Rijal S, Strub-Wourgaft N, Alves F, Alvar J, Sharma B.
    PLoS Negl Trop Dis; 2017 May 08; 11(5):e0005635. PubMed ID: 28558062
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial.
    Wasunna M, Njenga S, Balasegaram M, Alexander N, Omollo R, Edwards T, Dorlo TP, Musa B, Ali MH, Elamin MY, Kirigi G, Juma R, Kip AE, Schoone GJ, Hailu A, Olobo J, Ellis S, Kimutai R, Wells S, Khalil EA, Strub Wourgaft N, Alves F, Musa A.
    PLoS Negl Trop Dis; 2016 Sep 08; 10(9):e0004880. PubMed ID: 27627654
    [Abstract] [Full Text] [Related]

  • 10. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
    Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P, Modabber F.
    Lancet; 2011 Feb 05; 377(9764):477-86. PubMed ID: 21255828
    [Abstract] [Full Text] [Related]

  • 11. Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study.
    Musa AM, Younis B, Fadlalla A, Royce C, Balasegaram M, Wasunna M, Hailu A, Edwards T, Omollo R, Mudawi M, Kokwaro G, El-Hassan A, Khalil E.
    PLoS Negl Trop Dis; 2010 Oct 26; 4(10):e855. PubMed ID: 21049063
    [Abstract] [Full Text] [Related]

  • 12. Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India.
    Goyal V, Mahajan R, Pandey K, Singh SN, Singh RS, Strub-Wourgaft N, Alves F, Rabi Das VN, Topno RK, Sharma B, Balasegaram M, Bern C, Hightower A, Rijal S, Ellis S, Sunyoto T, Burza S, Lima N, Das P, Alvar J.
    PLoS Negl Trop Dis; 2018 Oct 26; 12(10):e0006830. PubMed ID: 30346949
    [Abstract] [Full Text] [Related]

  • 13. Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis.
    Gebreyohannes EA, Bhagvathula AS, Abegaz TM, Seid MA.
    Infect Dis Poverty; 2018 Oct 19; 7(1):108. PubMed ID: 30340519
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial.
    Khalil EA, Weldegebreal T, Younis BM, Omollo R, Musa AM, Hailu W, Abuzaid AA, Dorlo TP, Hurissa Z, Yifru S, Haleke W, Smith PG, Ellis S, Balasegaram M, EL-Hassan AM, Schoone GJ, Wasunna M, Kimutai R, Edwards T, Hailu A.
    PLoS Negl Trop Dis; 2014 Oct 19; 8(1):e2613. PubMed ID: 24454970
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial.
    Omollo R, Alexander N, Edwards T, Khalil EA, Younis BM, Abuzaid AA, Wasunna M, Njoroge N, Kinoti D, Kirigi G, Dorlo TP, Ellis S, Balasegaram M, Musa AM.
    Trials; 2011 Jun 30; 12():166. PubMed ID: 21718522
    [Abstract] [Full Text] [Related]

  • 16. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India.
    Jha TK, Olliaro P, Thakur CP, Kanyok TP, Singhania BL, Singh IJ, Singh NK, Akhoury S, Jha S.
    BMJ; 1998 Apr 18; 316(7139):1200-5. PubMed ID: 9583927
    [Abstract] [Full Text] [Related]

  • 17. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis.
    Thakur CP, Kanyok TP, Pandey AK, Sinha GP, Zaniewski AE, Houlihan HH, Olliaro P.
    Trans R Soc Trop Med Hyg; 2000 Apr 18; 94(4):429-31. PubMed ID: 11127250
    [Abstract] [Full Text] [Related]

  • 18. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
    Ritmeijer K, Dejenie A, Assefa Y, Hundie TB, Mesure J, Boots G, den Boer M, Davidson RN.
    Clin Infect Dis; 2006 Aug 01; 43(3):357-64. PubMed ID: 16804852
    [Abstract] [Full Text] [Related]

  • 19. Cytokine profiles, blood parasite load and clinical features of visceral leishmaniasis in West Pokot County, Kenya.
    van Dijk N, Carter J, Kiptanui D, Pinelli E, Schallig H.
    Parasitology; 2024 Jun 01; 151(7):753-761. PubMed ID: 39311405
    [Abstract] [Full Text] [Related]

  • 20. Injectable paromomycin for Visceral leishmaniasis in India.
    Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK.
    N Engl J Med; 2007 Jun 21; 356(25):2571-81. PubMed ID: 17582067
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.